Pfizer Inc (PFE)

34.26
NYSE : Health Care
Prev Close 34.15
Day Low/High 34.01 / 34.37
52 Wk Low/High 28.25 / 37.39
Avg Volume 19.49M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 207.14B
EPS 1.10
P/E Ratio 15.38
Div & Yield 1.20 (3.50%)

Latest News

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent fourth-quarter 2016 dividend on the company's common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Pull Those Stocks Up!

The market is just plain droopy.

Pfizer Announces Positive Top-Line Results From REFLECTIONS B537-02 Study For PF-06438179 (infliximab-Pfizer) A Potential Biosimilar To Remicade® (infliximab)

Pfizer Announces Positive Top-Line Results From REFLECTIONS B537-02 Study For PF-06438179 (infliximab-Pfizer) A Potential Biosimilar To Remicade® (infliximab)

Pfizer Inc. (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary...

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE ® (palbociclib) be...

Bought Aerie Earlier? Congratulations

Bought Aerie Earlier? Congratulations

An update on some recent small biotech recommendations.

Good News on Pfizer and Sonoco Products

FDA announcements and a price increase should be beneficial to these portfolio names.

Pfizer's (PFE) Chantix Warning Could Be Removed After FDA Recommendation

Pfizer's (PFE) Chantix Warning Could Be Removed After FDA Recommendation

Two FDA panels have recommended that it's most serious warning label be removed from the Pfizer (PFE) drug Chantix.

Merck And Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint Of A1C Reduction When Added To Sitagliptin And Metformin In People With Type 2 Diabetes

Merck And Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint Of A1C Reduction When Added To Sitagliptin And Metformin In People With Type 2 Diabetes

Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.

Allergan's Dealmaking Continues With Vitae Takeout

Allergan's Dealmaking Continues With Vitae Takeout

The $639 million deal marks the the third purchase for Brent Saunders since early August.

Allergan Is Doing All the Right Things

It is a matter of when, not if the market appreciates its potential.

Here's Why Pfizer Is Headed Lower Before It Can Head Higher

Here's Why Pfizer Is Headed Lower Before It Can Head Higher

For patient inventors, with more downside, Pfizer will reach a very low-risk entry zone.

Pfizer (PFE) Stock Falls, Jefferies Drops Price Target

Pfizer (PFE) Stock Falls, Jefferies Drops Price Target

Jefferies lowered its price target on Pfizer (PFE) to $39.

4 Market Segments to Avoid

4 Market Segments to Avoid

These sectors are full of high-priced, low-growth stocks.

Big Pharma Spends Millions to Keep Prices High for California Agencies

Big Pharma Spends Millions to Keep Prices High for California Agencies

Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.

Pfizer Launches New

Pfizer Launches New "Moodivator" App To Help Support, Encourage And Motivate People With Depression

Today, Pfizer Inc announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.

Pfizer Becomes #27 Most Shorted Dow Stock, Replacing Coca-Cola

Pfizer Becomes #27 Most Shorted Dow Stock, Replacing Coca-Cola

The most recent short interest data has been released for the 08/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Analysts Hit Reset Button On GlaxoSmithKline

Analysts Hit Reset Button On GlaxoSmithKline

A strong performance from the ViiV Healthcare venture and a foreign-exchange booster make the case for the U.K.'s leading pharmaceuticals business.

Will Pfizer (PFE) Stock Be Affected by FDA Chantix Study Scrutiny?

Will Pfizer (PFE) Stock Be Affected by FDA Chantix Study Scrutiny?

The FDA released a report on Monday questioning Pfizer's (PFE) recent study of the psychiatric effects of its smoking cessation drug Chantix.

Charts Show Something Broke Friday

Charts Show Something Broke Friday

Often, pictures speak louder than words.

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Pet Pharma Is the Newest Growth Sector

Pet Pharma Is the Newest Growth Sector

Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.

Nervous Pooch? There's a Drug for That

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.

Dive Safely Into These 12 Dividend Payers

Dive Safely Into These 12 Dividend Payers

If and when interest rates go up, this basket of stocks should continue to do well.